Literature DB >> 19830883

Minimal important differences in the Migraine-Specific Quality of Life Questionnaire (MSQ) version.

J C Cole1, P Lin, M F T Rupnow.   

Abstract

To propose minimal important differences (MID) for the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ v2.1). To our knowledge (to date), no published MID values exist for the MSQ v2.1 in any population. Analyses were performed on data from two pivotal clinical trials of topiramate for migraine prevention (n = 916), as well as from the QualityMetric National Headache Survey (n = 1016). Analyses included both distribution- and anchor-based MID techniques as well as group- and individual-level MID values. Group-level anchor-based MID values ranged from 3.2 [Role Restrictive domain (RR)] to 7.5 [Emotional Functioning domain (EF)], setting the minimum level of appropriate MID (which can also aid with power analysis). Individual-level distribution-based MID values resulted in highly similar estimates from two large databases: median MID of 8.5 for RR, 9.2 for Role Preventive (RP) and 12.0 for EF. Finally, individual-level anchor-based MID values ranged from 5.0 (RR and RP domains) to 10.6 (EF). For group-level purposes of calculating power for future studies, an MID of 3.2, 4.6 and 7.5 for RR, RP and EF is recommended. For within-group analyses for analysing clinical trial efficacy of each patient's change with responder analyses, 5 points is necessary for RR. For RP and EF, ranges are recommended: 5.0 to 7.9 for RP and 8.0 to 10.6 for EF. These latter two domains tend to have more error in the MID, and thus a sensitivity analysis with both ends of the range should be used to confirm significant differences in responder analyses.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19830883     DOI: 10.1111/j.1468-2982.2009.01852.x

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  25 in total

1.  Acupuncture for migraine prophylaxis: a randomized controlled trial.

Authors:  Ying Li; Hui Zheng; Claudia M Witt; Stephanie Roll; Shu-guang Yu; Jie Yan; Guo-jie Sun; Ling Zhao; Wen-jing Huang; Xiao-rong Chang; Hong-xing Zhang; De-jun Wang; Lei Lan; Ran Zou; Fan-rong Liang
Journal:  CMAJ       Date:  2012-01-09       Impact factor: 8.262

2.  Validating the Migraine-Specific Quality of Life Questionnaire v2.1 (MSQ) in Italian inpatients with chronic migraine with a history of medication overuse.

Authors:  Alberto Raggi; Ambra Mara Giovannetti; Silvia Schiavolin; Matilde Leonardi; Gennaro Bussone; Licia Grazzi; Susanna Usai; Marcella Curone; Paola Di Fiore; Domenico D'Amico
Journal:  Qual Life Res       Date:  2013-10-16       Impact factor: 4.147

Review 3.  Assessment of Quality of Life in Migraine.

Authors:  Özlem Taşkapilioğlu; Necdet Karli
Journal:  Noro Psikiyatr Ars       Date:  2013-08-01       Impact factor: 1.339

4.  The psychometric properties of the Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ) in chronic migraine patients.

Authors:  Regina Rendas-Baum; Lisa M Bloudek; Gregory A Maglinte; Sepideh F Varon
Journal:  Qual Life Res       Date:  2012-07-15       Impact factor: 4.147

5.  Unmet Needs in Japanese Patients Who Report Insufficient Efficacy with Triptans for Acute Treatment of Migraine: Retrospective Analysis of Real-World Data.

Authors:  Koichi Hirata; Kaname Ueda; Mika Komori; Wenyu Ye; Yongin Kim; Sarah Cotton; James Jackson; Tamas Treuer
Journal:  Pain Ther       Date:  2020-12-11

6.  Cerebrovascular Function in Hormonal Migraine: An Exploratory Study.

Authors:  Jemima S A Dzator; Peter R C Howe; Lyn R Griffiths; Kirsten G Coupland; Rachel H X Wong
Journal:  Front Neurol       Date:  2021-07-07       Impact factor: 4.003

7.  Long-term efficacy and safety of erenumab in migraine prevention: Results from a 5-year, open-label treatment phase of a randomized clinical trial.

Authors:  Messoud Ashina; Peter J Goadsby; Uwe Reuter; Stephen Silberstein; David W Dodick; Fei Xue; Feng Zhang; Gabriel Paiva da Silva Lima; Sunfa Cheng; Daniel D Mikol
Journal:  Eur J Neurol       Date:  2021-01-20       Impact factor: 6.089

8.  Determinants of health-related quality of life in school-aged children: a general population study in the Netherlands.

Authors:  Marieke Houben-van Herten; Guannan Bai; Esther Hafkamp; Jeanne M Landgraf; Hein Raat
Journal:  PLoS One       Date:  2015-05-01       Impact factor: 3.240

9.  Effects of fremanezumab in patients with chronic migraine and comorbid depression: Subgroup analysis of the randomized HALO CM study.

Authors:  Richard B Lipton; Joshua M Cohen; Maja Galic; Michael J Seminerio; Paul P Yeung; Ernesto Aycardi; Marcelo E Bigal; Kristen Bibeau; Dawn C Buse
Journal:  Headache       Date:  2021-04       Impact factor: 5.887

10.  OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program.

Authors:  S K Aurora; D W Dodick; H-C Diener; R E DeGryse; C C Turkel; R B Lipton; S D Silberstein
Journal:  Acta Neurol Scand       Date:  2013-09-20       Impact factor: 3.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.